Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases

被引:21
作者
Amir, Omalhassan [1 ]
Hassan, Yahaya [1 ]
Sarriff, Azmi [1 ]
Awaisu, Ahmed [1 ]
Aziz, Noorizan Abd [1 ]
Ismail, Omar [2 ]
机构
[1] Univ Sains Malaysia, Dept Clin Pharm, Sch Pharmaceut Sci, George Town 11800, Malaysia
[2] Penang Gen Hosp, Dept Cardiol, George Town 10990, Malaysia
来源
PHARMACY WORLD & SCIENCE | 2009年 / 31卷 / 03期
关键词
ACE-inhibitors; Drug-drug interactions; Hyperkalemia; Incidence; Risk factors; LIFE-THREATENING HYPERKALEMIA; CONVERTING ENZYME-INHIBITORS; ADVERSE DRUG EVENTS; HEART-FAILURE; COMBINED THERAPY; SPIRONOLACTONE; POTASSIUM; DYSFUNCTION; CREATININE; MORTALITY;
D O I
10.1007/s11096-009-9288-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study objective To determine the incidence of and the risk factors associated with hyperkalemia, induced by ACEI-drug interactions among cardiac patients. Setting Five medical and cardiology wards of a tertiary care center in Malaysia. Subjects Five hundred cardiac inpatients, who received ACEIs concomitantly with other interacting drugs. Method This was a prospective cohort study of 500 patients with cardiovascular diseases admitted to Penang Hospital between January to August 2006, who received ACEIs concomitantly with other interacting drugs. ACEI-drug interactions of clinical significance were identified using available drug information resources. Drug Interaction Probability Scale (DIPS) was used to assess the causality of association between ACEI-drug interactions and the adverse outcome (hyperkalemia). Main outcome measure Hyperkalemia as an adverse clinical outcome of the interaction was identified from laboratory investigations. Results Of the 489 patients included in the analysis, 48 (9.8%) had hyperkalemia thought to be associated with ACEI-drug interactions. Univariate analysis using binary logistic regression revealed that advanced age (60 years or more), and taking more than 15 medications were independent risk factors significantly associated with hyperkalemia. However, current and previous smoking history appeared to be a protective factor. Risk factors identified as predictors of hyperkalemia secondary to ACEI-drug interactions by multi-logistic regression were: advanced age (adjusted OR 2.3, CI 1.07-5.01); renal disease (adjusted OR 4.7, CI 2.37-9.39); hepatic disease (adjusted OR 5.2, CI 1.08-25.03); taking 15-20 medications (adjusted OR 4.4, CI 2.08-9.19); and taking 21-26 medications (adjusted OR 9.0, CI 1.64-49.74). Conclusion Cardiac patients receiving ACEIs concomitantly with potentially interacting drugs are at high risk of experiencing hyperkalemia. Old age, renal disease, hepatic disease, and receiving large number of medications are factors that may significantly increase their vulnerability towards this adverse outcome; thus, frequent monitoring is advocated.
引用
收藏
页码:387 / 393
页数:7
相关论文
共 41 条
[1]   The safety of spironolactone treatment in patients with heart failure [J].
Anton, C ;
Cox, AR ;
Watson, RDS ;
Ferner, RE .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2003, 28 (04) :285-287
[2]   Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine - Is this a cause for concern? [J].
Bakris, GL ;
Weir, MR .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (05) :685-693
[3]   Patient risk factors for adverse drug events in hospitalized patients [J].
Bates, DW ;
Miller, EB ;
Cullen, DJ ;
Burdick, L ;
Williams, L ;
Laird, N ;
Petersen, LA ;
Small, SD ;
Sweitzer, BJ ;
Vander Vliet, M ;
Leape, LL .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (21) :2553-2560
[4]  
BENTE G, 2005, EUR J CLIN PHARMACOL, V61, P675, DOI DOI 10.1007/S00228-005-0978-6
[5]  
*BNF, 2007, BRIT R P S O G
[6]   Spironolactone therapy in older patients - the impact of renal dysfunction [J].
Butler, JV ;
McAvoy, H ;
McEnroy, D ;
Mulkerrin, EC .
ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2002, 35 (01) :45-49
[7]  
CHAN LN, 2000, PHARMACOTHERAPY SELF, P102
[8]   Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone [J].
Cruz, CS ;
Cruz, AA ;
de Souza, CAM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (09) :1814-1819
[9]   Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: A retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials [J].
de Denus, Simon ;
Tardif, Jean-Claude ;
White, Michel ;
Bourassa, Martial G. ;
Racine, Normand ;
Levesque, Sylvie ;
Ducharme, Anique .
AMERICAN HEART JOURNAL, 2006, 152 (04) :705-712
[10]  
Field A., 2005, DISCOVERING STAT USI, P208